In vivo proton magnetic resonance spectroscopy (1H-MRS) evaluation of the metabolite concentration of optic radiation in primary open angle glaucoma by unknown
NEURO
In vivo proton magnetic resonance spectroscopy (1H-MRS)
evaluation of the metabolite concentration of optic radiation
in primary open angle glaucoma
Sabrilhakim Sidek1,3 & Norlisah Ramli1 & Kartini Rahmat1 & Norlina Mohd Ramli2 &
Fadzlina Abdulrahman2 & Tan Li Kuo1
Received: 1 July 2015 /Revised: 4 February 2016 /Accepted: 8 February 2016 /Published online: 4 March 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Objective To compare the metabolite concentration of optic
radiation in glaucoma patients with that of healthy subjects
using Proton Magnetic Resonance Spectroscopy (1H-MRS).
Methods 1H-MRS utilising the Single-Voxel Spectroscopy
(SVS) technique was performed using a 3.0Tesla MRI on 45
optic radiations (15 from healthy subjects, 15 from mild glau-
coma patients, and 15 from severe glaucoma patients). A
standardised Volume of Interest (VOI) of 20×20×20 mm
was placed in the region of optic radiation. Mild and severe
glaucoma patients were categorised based on the Hodapp–
Parrish–Anderson (HPA) classification. Mean and multiple
group comparisons for metabolite concentration and metabo-
lite concentration ratio between glaucoma grades and healthy
subjects were obtained using one-way ANOVA.
Results The metabolite concentration and metabolite concen-
tration ratio between the optic radiations of glaucoma patients
and healthy subjects did not demonstrate any significant dif-
ference (p>0.05).
Conclusion Our findings show no significant alteration of
metabolite concentration associated with neurodegeneration
that could be measured by single-voxel 1H-MRS in optic
radiation among glaucoma patients.
Key Points
• Glaucoma disease has a neurodegenerative component.
• Metabolite changes have been observed in the neurodegen-
erative process in the brain.
• Using SVS, no metabolite changes in optic radiation were
attributed to glaucoma.
Keywords Glaucoma . Neurodegeneration . Spectroscopy .
Magnetic resonance imaging .Metabolites
Abbreviations
Ala L-alanine
ANOVA Analysis of variance
Asp Aspartate
Cho Choline
CNS Central nervous system
Cr Creatine
CrCH2 Creatine methylene
CRLB Cramer-Rao lower bound
DTI Diffusion tensor imaging
FOV Field of view















1 Department of Biomedical Imaging, University Malaya Research
Imaging Centre (UMRIC), University of Malaya, Lembah Pantai,
50603 Kuala Lumpur, Malaysia
2 Department of Ophthalmology, Faculty of Medicine, University of
Malaya, Lembah Pantai, 50603 Kuala Lumpur, Malaysia
3 Medical Imaging Unit, Faculty of Medicine, Universiti Teknologi
MARA, Sg Buloh Campus, 47000 Sg Buloh, Selangor, Malaysia
Eur Radiol (2016) 26:4404–4412
DOI 10.1007/s00330-016-4279-5
MRI Magnetic resonance imaging
n Number of subjects
NAA N-acetyl aspartate
NAAG N-acetyl aspartylglutamate




PRESS Point-resolved single-voxel spectroscopy
RNFL Retinal nerve fibre layer
SD Standard deviation
SPSS Statistical Package for the Social Sciences
SVS Single-voxel spectroscopy
tCho GPC + PCh
tCr Cr + PCr
tNAA NAA + NAAG
TE Echo time
TR Repetition time
1H-MRS Proton magnetic resonance spectroscopy
RGC Retinal ganglion cell
VBM Voxel-based morphometry
VOI Volume of interest
%SD Percentage standard deviation for CRLB
or CRLB percentage value
Introduction
Glaucoma is an irreversible neurodegenerative disease
and the second most common cause of blindness world-
wide [1]. Retinal Ganglion Cell (RGC) death and visual
pathway axonal degeneration contribute to glaucoma.
The pathophysiology of glaucoma is believed to be mul-
tifactorial. Irrespective of the site of neuronal injury, fac-
tors, or mechanisms involved, the terminal outcome is
the death of RGCs and their axons, thus resulting in
irreversible visual loss [2].
Anatomical changes reflecting damage to the optic nerve
(ON) head and retinal nerve fibre layer (RNFL) are the basis
for glaucoma diagnosis and evaluation. Recent studies have
broadened the theory of the neurodegenerative process of
glaucoma beyond the ON per se to involve the entire visual
pathway through assessment methods utilising newer and
more advanced MRI techniques [3–7].
Previous morphological studies evaluated the volume
changes in various specific structures in the brain in pa-
tients with glaucoma [8–11]. Using MRI Voxel-Based
Morphometry (VBM), Hernowo et al. found significant
volume reduction in all structures of the visual pathways,
including optic radiations [8]. In the occipital lobe, MRI
volumetric studies were specifically focused on the visu-
al and visual association cortices. Recent publications
observed significant cortical thinning in the occipital
lobe using volumetric MRI techniques or volume reduc-
tion of the visual cortices in patients with glaucoma
[9–11]. Diffusion Tensor Imaging (DTI) corroborated
the findings of decreased microstructural white matter
integrity in optic radiations among patients with glauco-
ma [7, 12]. Interestingly, other MRI volumetric studies
conducted by William et al., Li et al. and Chen et al.
showed volumetric gains and a decrease in several struc-
tural components of the visual cortices in the occipital
lobe [13–15].
To the best of our knowledge, only a few studies on the
changes in metabolite concentrations in the visual pathway
related to glaucoma disease have been previously published,
and these studies demonstrated various findings [16–19].
Boucard et al. published the earliest findings on metabolite
changes in seven glaucoma and seven age-related macular
degeneration patients compared with 12 healthy subjects.
They found no significant metabolite changes for NAA/Cr,
Cho/Cr, and Glx/Cr in the occipital lobe of each subject using
the single-voxel 1H-MRS technique [16].
By contrast, Doganay et al. studied single-voxel 1H-MRS
on the LGB and corpus vitreous of 29 glaucoma patients and
13 healthy subjects [17]. They found statistically significant
reduction of Glx/Cr ratio in both vitreous body and LGB, but
no metabolite alteration in NAA/Cr and Cho/Cr ratios in the
LGB. Additionally, they found a lactate peak in the vitreous
body of 11 glaucoma patients.
In the most recent study conducted by Yan Zhang et al.,
changes in metabolite concentration were found in primary
glaucoma using multi-voxel 1H-MRS at the geniculocalcarine
tract (GCT) and striate areas [18]. They studied 20 glaucoma
patients who were age- and gender-matched to 20 healthy
volunteers. Significant reductions in NAA/Cr and Cho/Cr
were found in the geniculocalcarine and striate areas of glau-
coma subjects compared with healthy subjects [18].
Using an experimental rat model, Kevin et al. conducted a
1H-MRS study on glaucoma and found a significant Cho/Cr
reduction in the left visual cortex side of induced glaucoma as
compared with the right side. No significant difference was
observed in other metabolites, including NAA and Glx [19].
1H-MRS is a non-invasive technique that enables the de-
tection, identification, and quantification of biochemical com-
pounds or metabolites in the brain tissue. This approach pro-
vides physiological and chemical information [20].
Metabolites that can be measured using 1H-MRS include N-
acetyl aspartate (NAA), choline (Cho), creatine (Cr), lactate,
glutamine, glutamate, lipids, and macromolecules [21]. In
their review article, Soares et al. accurately described the func-
tions of each metabolite, as well as the position of the respec-
tive metabolite’s peak on the spectrum [22]. In addition, Ross
et al. described the alteration in metabolite concentration as-
sociated with many diseases across the ages. These conditions
include brain hypoxia, inborn errors of metabolism, tumours,
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white matter disease, trauma prognosis, and stroke [23]. Other
conditions, such as epilepsy, diabetic coma, and hepatic en-
cephalopathy, were also reported to cause changes in metab-
olite concentration in the brain [24].
In this study, we applied single-voxel 1H-MRS using a 3 T
scanner to the optic radiations to identify any significant me-
tabolite changes between healthy subjects and patients with
mild and severe glaucoma.
Materials and methods
This cross-sectional study was conducted from October 2010
to September 2012. Ethical approval was obtained from the
institutional medical review board. Forty-five optic radiations,
which demonstrated good, acceptable spectroscopy curves,
were selected. Two neuroradiologists performed visual in-
spection of the individual spectra (NR & KR). The reliability
and quality of the spectroscopy curves were characterised by
modelling the normal distribution of the estimated percentage
standard deviations (%SD) on a per-metabolite basis.
The total number of subjects involved in this study was 26,
for a total of 52 optic radiations. Forty-five optic radiations
were selected, whereas seven optic radiations were excluded
from this study after spectral characterisation and visual
review.
All subjects were enrolled from the ophthalmology clinic
of a single tertiary teaching hospital. Informed consent was
obtained from each subject. The recruited subjects underwent
a comprehensive ophthalmological assessment that included a
slit lamp examination, standard automated perimetry using the
24-2 program of the Humphrey Visual Field Analyser (Carl
Zeiss Meditec, Dublin, CA, USA), and retinal nerve fibre
layer thickness using the Cirrus High Definition-Optical
Coherence Tomography (HD-OCT) machine (Carl Zeiss
Meditec, Dublin, CA, USA). An experienced consultant oph-
thalmologist (NMR) assessed the glaucoma severity based on
the Hodapp–Parrish–Anderson (HPA) classification system
[25]. Briefly, this classification is based on Mean Deviation
(MD) scores on Humphrey Visual Field testing. Mild glauco-
ma refers to those withMD of less than −6 dB, whereas severe
glaucoma refers to those with MD greater than −12 dB. The
inclusion criterion was patients with bilateral symmetrical dis-
ease from primary open angle glaucoma. The exclusion
criteria were as follows: (1) patients under 18 years of age,
(2) with secondary glaucoma; and (3) with history of any
central nervous system (CNS) disorder, including small vessel
ischaemic white matter disease found on the initial MRI.
The healthy subjects were either relatives accompanying the
subjects or those who attended the clinic for non-glaucoma-
related problems. Standard routine ophthalmological investiga-
tions, which included slit lamp examination, intraocular pressure
measurement with the Goldman tonometer, and optic disc as-
sessment, were performed. Those with large cup disc ratios of
0.7 ormore or who had any features suggestive of glaucomatous
optic neuropathy were excluded. The demographic information
is summarised in Table 1. The larger cohort of healthy subjects
and glaucoma patients had undergone concurrentMRI volumet-
ric optic nerve measurement and Diffusion Tensor Imaging
(DTI) of the optic nerve and optic radiation, the results of which
had recently been published [6, 7].
MRI acquisition
All participants were scanned on the 3.0Tesla MRI scanner
(Signa Hdx General Electric Healthcare, Milwaukee, WI,
USA) equipped with a dedicated eight-channel head coil.
We performed high resolution anatomic T1 weighted fast
spoiled gradient echo (FSPGR) using these sequence param-
eters; TR=7.6 ms, TE=2.1–12 ms, FOV=31×31 cm, ma-
trix = 256 × 256, slice thickness = 1.2 mm iso-voxel, slice
overlap=0.6 mm, and image scan time of 3 min and 48 s.
TE time ranged between 2.1 and 12 ms for the imaging acqui-
sition to accommodate the coverage. We utilised the Single-
voxel spectroscopy (SVS) technique using a point-resolved
single-voxel spectroscopy (PRESS) probe-p sequence with
Table 1 Patient demographics
with glaucoma grading Healthy subjects Mild glaucoma Severe glaucoma
Number of optic radiation 15 15 15
Gender Male 12 (80 %) 6 (40 %) 9 (60 %)
Female 3 (20 %) 9 (60 %) 6 (40 %)
Age (mean ± SD in years) 53.9 (± 8.0) 64.9 (± 8.2) 69.7 (± 8.2)
Mean RNFL thickness (μm) Right eye 84.47 ± 10.44 76.37 ± 11.35 58.50 ± 6.97
Left eye 83.60 ± 10.36 76.87 ± 12.01 58.60 ± 9.05
Visual field MD scores (dB) Right eye −0.99 ± 0.92 −3.95± 1.40 21.98 ± 7.35
Left eye −0.90 ± 0.84 −4.05± 1.15 20.17 ± 9.46
SD standard deviation, RNFL retinal nerve fibre layer, MD mean deviation
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echo time (TE) of 35 ms and repetition time (TR) of 1500 ms.
Other acquis i t ion parameters were VOI s ize of
20 × 20 × 20 mm, matrix of 1.0 × 1.0, slice thickness of
20 mm, number of excitation (NEX)=128, and scan time of
3 min and 48 s. The axial, coronal, and sagittal multi-planar
3D reformatted FSPGR images were used to position a single
voxel in the optic radiations. The VOI was placed on the optic
radiations of each cerebral hemisphere and standardised along
the calcarine sulcus, as far back as the occipital lobe and to-
wards the midline of the brain (Fig. 1). To mitigate shimming
and water suppression effects, the VOI placement, as well as
contact with the bone, subcutaneous fat, vasculature, and other
tissues, was avoided [16].
The raw data (P-files) obtained from the SVSmeasurement
were then transferred and saved into a Linux system. Post-
processing was performed using the LCModel Software
Version 6.2 © 1992–2010 by Stephen Provencher (V6.2,
LCMODEL Inc., Canada) [26], where the spectra were fitted,
and the metabolites were quantified. The standard basis set
provided by LCModel was used, and no spectral apodization
was performed. The data are zero-filled once in LCModel.
This puts all the information in the real part of the spectrum.
Further zero-filling adds no information [27]. The reliability
of the metabolite quantification was characterised by model-
ling the normal distribution of the estimated percentage stan-
dard deviations (%SD) on a per-metabolite basis. Specifically,
the %SD mean and standard deviation within the control
group were determined for each metabolite. A 95 % confi-
dence limit (approximately, mean + 2 × standard deviation)
was calculated, and all values with %SD exceeding the re-
spective %SD limit were omitted from further analysis. We
activated all the metabolites, lipids and macromolecules in
LCModel; however, in this article, we were focusing on
NAA, NAAG, Cr, PCr, GPC, PCh, Gln and Glu measurement
(Fig. 2). Our concentrations were in ‘institutional units’, self-
consistent, but equal to mM per Kg wet tissue weight by an
unknown factor.
In this study, the total choline concentration was derived
from the sum of glycerophosphocholine (GPC) and
phosphocholine (PCh), with the variable represented as
tCho. Total creatine concentration was derived from the sum
of creatine (Cr) and phosphocreatine (PCr), with the variable
represented as tCr. Total glutamate-glutamine was derived
from the sum of glutamate (Glu) and glutamine (Gln), with
the variable represented as Glx. Total N-acetyl aspartate was
derived from the sum of N-acetyl aspartate (NAA) and N-
acetylaspartylglutamate (NAAG), with the variable represent-
ed as tNAA.
Statistical analysis
Statistical analyses were performed using the SPSS Version
19.0 (SPSS Inc., Chicago, IL, USA). Multiple group compar-
isons for metabolite concentration and metabolite concentra-
tion ratio between glaucoma grades and healthy subjects were
obtained using a one-way ANOVA test for each criterion. A p
value of<0.05 was considered statistically significant.
Results
Analyses of 45 optic radiations showed findings consistent
with a good, acceptable spectroscopy curve. No significant
difference in mean age was observed between the mild and
severe glaucoma subjects (p>0.05). A significant difference
in the mean age was noted between healthy and mild glauco-
ma subjects and between healthy and severe glaucoma sub-
jects (p<0.05).
Mean (±SD) metabolite concentration and metabolite con-
centration ratio to tCr are shown in Tables 2 and 3. We found
no significant difference (p>0.05) between metabolite con-
centration and metabolite concentration ratio in the optic radi-
ations of healthy subjects, mild glaucoma patients, and severe
glaucoma patients. Concentration ratios of tNAA/tCr, tCho/
tCr, and Glx/tCr for the healthy subjects and the mild and
severe glaucoma groups regarding optic radiation were illus-
trated in a boxplot (Fig. 3).
Fig. 1 VOI placement in the
optic radiations using FSPGR
sequence 3D reconstruction in the
(a) sagittal, (b) axial, and (c)
coronal views. Arrows indicate
the VOI placement
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We also performed analysis of our data based on Cramer-
Rao lower bound (CRLB) with %SD of less than 20 % as
recommended by previous studies using the LCModel
[28–31]. We found significant difference in tNAA between
mild (mean±SD of 3.75±0.21) and severe glaucoma groups
(mean±SD of 3.34±0.46) with p=0.012. No significant dif-
ference (p>0.05) was found between healthy subject (mean
±SD of 3.48±0.39) and mild glaucoma, as well as healthy
Table 2 Mean values of different
metabolite concentrations among
healthy and glaucoma subjects
(based on per-metabolite basis)
Metabolites Healthy subjects Mild glaucoma Severe glaucoma p value
n Mean (±SD) n Mean (±SD) n Mean (±SD)
Creatine (Cr) 7 0.92 ± 0.31 11 1.03± 0.25 5 0.97± 0.25 0.627
Phosphocreatine (PCr) 7 1.24 ± 0.26 11 1.24± 0.23 5 1.40± 0.24 0.479
Glutamine (Gln) 7 1.84 ± 0.66 11 2.02± 0.47 5 2.14± 0.48 0.336
Glutamate (Glu) 7 2.95 ± 0.27 11 2.95± 0.42 5 3.12± 0.81 0.734
Glycerophosphocholine (GPC) 7 0.53± 0.06 11 0.54± 0.09 5 0.59± 0.12 0.287
N-Acetylaspartate (NAA) 7 3.14± 0.18 11 3.25± 0.25 5 3.30± 0.43 0.210
N-Acetylaspartylglutamate
(NAAG)
7 0.42± 0.16 11 0.53± 0.16 5 0.55± 0.29 0.798
GPC + PCh (tCho) 7 0.53± 0.06 11 0.54± 0.09 5 0.59± 0.12 0.287
NAA + NAAG (tNAA) 7 3.57± 0.26 11 3.78± 0.21 5 3.83± 0.32 0.088
Glu + Gln (Glx) 7 4.79 ± 0.78 11 4.97± 0.59 5 5.33± 0.50 0.311
Cr + PCr (tCr) 7 2.15 ± 0.15 11 2.28± 0.24 5 2.37± 0.28 0.103
Data were expressed as mean (±SD) and analysed using one-way ANOVA. n number of subjects, SD standard
deviation
Fig. 2 Example of a good, acceptable spectroscopy spectrum from an optic radiation of a healthy subject
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subjects and severe glaucoma groups. We have also noted that
the p value for Gln was 0.001. However, statistically, the sig-
nificant value was not reliable. This was due to statistical
limitation to perform post Hoc tests because at least one group
has fewer than two cases. Otherwise, there was no significant
difference found for other metabolites, as well as between
metabolite concentration ratio and tCr (p>0.05).
The range of metabolite concentration ratio in the optic
radiation among healthy subjects was determined. The range
for tNAA/tCr was 1.3 to 1.9, that for tCho/tCr was 0.2 to 0.3,
and that for Glx/tCr was 1.8 to 2.9.
Discussion
In our study, using CRLB analysis with %SD of less than
20 % [28–31], we found a spurious increase in the mean of
tNAA in mild glaucoma compared to severe glaucoma
groups, causing a significant difference in the p value.
However, analysis of the data by modelling the normal distri-
bution of the estimated percentage standard deviations (%SD)
on a per-metabolite basis, tNAA concentration was found to
be non-significant across the groups. The differences in the
findings were attributed to the comparison of absolute CRLB
to those of the healthy subject group. The CRLB to normal
metabolite levels as shown in this study was more useful as
quality criteria [32]. Furthermore, bias could also be avoided,
as low levels of metabolite concentrations of interest was also
included in the analysis [32].
Either using CRLB with %SD<20 % or absolute CRLB
(with comparison to the healthy subject), the metabolite con-
centration ratios (tNAA/tCr, tCho/tCr and Glx/tCr) were
found to be nonsignificant across the glaucoma grades and
healthy subjects.Metabolite concentration ratios are more sen-
sitive regarding detecting changes, and can be more accurate
than absolute concentration due to application of specific
characteristics in the computer program analysis [33, 34].
Therefore, from this study, the ratio of metabolite
Table 3 Mean concentration
ratios of tNAA/tCr, tCho/tCr, and
Glx/tCr among healthy and
glaucoma subjects (based on per-
metabolite basis)
Metabolite ratio Healthy subjects Mild glaucoma Severe glaucoma p value
n Mean (±SD) n Mean (±SD) n Mean (±SD)
tNAA/tCr 15 1.63± 0.17 15 1.67 ± 0.12 15 1.55± 0.16 0.23
tCho/tCr 15 0.24± 0.03 15 0.24 ± 0.03 15 0.25 ± 0.03 0.80
Glx/tCr 15 2.20± 0.30 15 2.19 ± 0.26 15 2.24± 0.26 0.86
Data were expressed as mean (±SD) and analysed using one-way ANOVA. n number of subjects, SD standard
deviation
Fig. 3 Boxplot illustrating
concentration ratios of tNAA,
tCho, and Glx to tCr for the
healthy subjects and the mild and
severe glaucoma groups in terms
of optic radiations (based on per-
metabolite basis)
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concentration to creatine was more reliable to represent the
changes in optic radiations. Our results corroborated the find-
ings of Boucard et al., who concluded that progressive retinal
visual field defects do not affect absolute metabolite concen-
tration in optic radiations, thus implying the absence of on-
going occipital degeneration attributable to slow detectable
metabolite changes [16].
From this study, we also obtained the ranges of metabolite
ratios in optic radiation among healthy subjects. The ranges
for the tNAA/tCr, tCho/tCr, and Glx/tCr ratios were 1.3 to 1.9,
0.2 to 0.3, and 1.8 to 2.9 m, respectively. The differences
between the ranges obtained in this study from those obtained
in other studies on healthy subjects may be attributed to the
site of measurement. This is supported by previous studies
performed by Ludovico et al., Pouwels et al., and Grachev
et al., who all found various significant metabolite concentra-
tions across regional normal brain structures, owing to the
chemical heterogeneity of the human brain [35–37].
A study conducted by Yan Zhang et al. revealed a signifi-
cant reduction in NAA/Cr and Cho/Cr in primary glaucoma
using multi-voxel 1H-MRS [18]. The reasons for the differ-
ences between our study and this study may be attributed to
the differences in the applied technique, with the previous
work using ratios instead of absolute measurements and
multi-voxel instead of SVS, and in the site of measurement.
Multi-voxel spectroscopy obtains multiple single-voxel spec-
tra, which can reduce the partial volume effect while acquiring
a higher signal because of its large view, which can reflect the
spatial distribution of metabolites. However, the capability of
multi-voxel spectroscopy for multi-dimensional data acquisi-
tion is more appropriate for the measurement of diffuse, inho-
mogeneous, and large areas of pathological changes in
the brain, such as a tumour. In this research, we con-
sidered a specific region, which was the optic radiation,
such that we did not require the use of multi-voxel.
Furthermore, a few disadvantages, such as insufficient
water suppression, poor shimming, and voxel bleeding,
contribute to inability to acquire high-quality spectra in
multi-voxel [38].
Another study byDoganay et al. [17] differs from our study
with respect to the site of measurement. There were indeed
differences in both technique and patient selection. Their
study had 13 normal patients, and two mild glaucoma, 18
moderate and nine severe glaucoma patients according to
Hodapp Anderson criteria. Ours had 15 normal, 15 mild and
15 severe. Hence it is not entirely comparable as they had
more numbers of ‘diseased’ patients. More importantly, in
terms of technique as well, they looked at concentrations in
vitreous (within the eyeball) and lateral geniculate body
(LGB). Our study looked at more distal sites in the optic
radiations. They found significant positive differences at level
of vitreous for lactate and Glx/Cr, but not in LGB. This im-
plies that the primary site of metabolite differences lies more
proximal in location, nearer to optic nerve rather than further
down the optic tracts. They also did not specify who of these
11 patients had significant differences, what grade of glauco-
ma severity they had and whether it correlated with disease
severity or not. Therefore, future research area should concen-
trate on metabolite differences in areas more proximal, i.e.,
vitreous and optic nerve, since our results demonstrated no
significant change in the optic radiations despite clinical evi-
dence of severe glaucoma.
Chan et al. carried out an in vivo spectroscopy study of
glaucoma in rats where ocular hypertension was unilaterally
induced in the right eye of five Sprague–Dawley rats [19].
Single-voxel 1H-MRS was performed after 6 weeks of induc-
tion at the left visual cortex. The left eye and right visual
cortex were considered as internal control. They found signif-
icant Cho/Cr reduction in the left visual cortex compared with
the right. No significant difference was observed in the other
metabolites, including NAA and Glx. Therefore, they con-
cluded that glaucoma alters choline metabolism in the visual
cortex [19]. This finding needs to be confirmed in human
studies.
A major limitation of our study is the small size of optic
radiation compared with the size of the spectroscopic volume
of interest. Our area of measurement may be also too distal to
the area of primary degeneration, which occurs at the level of
the optic nerve head in glaucoma. Another study that focuses
on the metabolite concentrations within the optic nerves or
optic tracts may yield significant results. The difference in
mean age between the healthy and the mild glaucoma group,
as well as between the healthy and severe glaucoma groups,
could also be a limiting factor in our study. Patients with mild
and severe glaucoma are significantly older than those in the
control group. This is a limitation of the study, given that
metabolite concentrations were reported to change slightly
with age [39, 40]. Nevertheless, this condition is not likely
to affect the results of this study. Also, we did not perform
test-retest analysis to obtain real reproducibility findings in
this study.
In conclusion, the result of this cross-sectional study
showed that no significant metabolite changes in the optic
radiation were associated with glaucoma and its severity,
which could be measured by single-voxel 1H-MRS.
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